October 2, 2025Expert Review of VaccinesOpen Access

Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule

View Full Paper

Ask AI

Bookmark

The study indicates that PCV20 may elicit stronger immune responses than PCV15 in young children, highlighting the potential benefits of newer vaccines.
Key evidence shows a substantial difference in immunogenicity, specifically in the antibody levels elicited against various pneumococcal serotypes.
Indirect comparison analyzed immune responses from infants and toddlers who received either PCV15 or PCV20 in a 2 + 1 schedule.
The findings suggest that the choice of pneumococcal vaccine could significantly impact immunization strategies for childhood health.

Implication

Indirect comparison of immune responses between PCV15 and PCV20 in healthy infants and toddlers suggests important differences.

Abstract

Background Clinical trials have compared new pneumococcal conjugative vaccines (PCVs; PCV15 and PCV20) to an established PCV (PCV13) in a routine 2 + 1 schedule. This study performed an indirect comparison of PCV15 vs. PCV20 immune responses in healthy infants and toddlers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mt‐Isa et al. (2025) studied this question.

synapsesocial.com/papers/68de8eaeaa6cec72c69ea7e8 https://doi.org/10.1080/14760584.2025.2569037

View Full Paper

Ask AI

Bookmark

Implication

Indirect comparison of immune responses between PCV15 and PCV20 in healthy infants and toddlers suggests important differences.

Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule

Key Points

Implication

Abstract

Discussion

Cite This Study

Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule

Key Points

Implication

Abstract

Discussion

Cite This Study